Co (market cap: $42.4 billion) reported robust Q4 2024 earnings, exceeding Wall Street forecasts with adjusted earnings per share (EPS) of $0.99, compared to the expected $0.82. Revenue also surpassed ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.